Study S001234

Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01847313
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 20
Start: 2013-04
Primary completion: 2015-11
Lead sponsor: Karl Neff
Conditions: Diabetic Kidney Disease
Interventions: DRUG:Liraglutide
Results posted: TRUE

Registered primary outcomes

MCP-1:Creatinine Ratio in Urine [Up to 26 weeks]

Linked records (8)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT01847313; registry reference DERIVED:39963952
R0020698	Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. Ahern T, Journal of the European Academy of Dermatology and Venereology : JEADV	2013	Nonrandomized study	PMID 22691169 DOI	registry reference BACKGROUND:22691169
R0014008	Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Kodera R, Diabetologia	2011	Preclinical	PMID 21253697 DOI	registry reference BACKGROUND:21253697
R0018897	Glucagon-like peptide analogues for type 2 diabetes mellitus. Shyangdan DS, The Cochrane database of systematic reviews	2011	Systematic review	PMID 21975753 DOI	registry reference BACKGROUND:21975753
R0021902	Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Hogan AE, Diabetologia	2011	Preclinical	PMID 21744074 DOI	registry reference BACKGROUND:21744074
R0020040	Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Pinkney J, Therapeutics and clinical risk management	2010	Narrative review	PMID 20856686 DOI	registry reference BACKGROUND:20856686
R0021555	Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Cummings BP, Diabetes	2010	Preclinical	PMID 20622169 DOI	registry reference BACKGROUND:20622169
R0021980	Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Jacobsen LV, British journal of clinical pharmacology	2009	Nonrandomized study	PMID 20002084 DOI	registry reference BACKGROUND:20002084